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ABSTRACT: The ATP site of kinases displays remarkable
conformational ﬂexibility when accommodating chemically
diverse small molecule inhibitors. The so-called activation
segment, whose conformation controls catalytic activity and
access to the substrate binding pocket, can undergo a large
conformational change with the active state assuming a ‘DFG-
in’ and an inactive state assuming a ‘DFG-out’ conformation.
Compounds that preferentially bind to the DFG-out
conformation are typically called ‘type II’ inhibitors in contrast
to ‘type I’ inhibitors that bind to the DFG-in conformation.
This review surveys the large number of type II inhibitors that
have been developed and provides an analysis of their crystallographically determined binding modes. Using a small library of
type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be
intrinsically more selective than type I inhibitors.
K
inases represent one of the largest enzyme families whose
three-dimensional structures are largely conserved from
simple prokaryotes to humans. By functioning within complex
and intercommunicating networks, kinases serve as a funda-
mentalbuildingblockthatallowscellstocomputeanappropriate
biologicalresponsetoaparticularstimulation.
1Itisthereforenot
surprising that deregulation of kinases as a result of transcrip-
tional, mutational, or post-translational modiﬁcations can lead to
inappropriate cellular responses and ultimately to disease. Over
thepasttwodecades,intensivedrugdiscoveryeﬀorts,particularly
those targeting mutationally activated kinases or oncogenic
kinase fusion proteins such as BRAF, PI3K, BCR-ABL, EML4-
ALK, EGFR, and c-KIT, have resulted in the approval of 23 ATP
competitive kinase inhibitor drugs with a large number of
additional compounds advancing in clinical and preclinical
development.
2,3Estimatessuggestthatderegulationofabout180
kinases is associated with disease, particularly cancer, and
approximately 40 kinases are being actively pursued by drug
discovery programs.
4
The majority of small molecule kinase inhibitors bind in or
around the nucleotide binding cleft, thereby preventing ATP
from binding. The large number of available X-ray crystal
structures in the public domain have revealed a multitude of
diﬀerent ways of small molecules can be recognized in and
around the ATP-binding cleft. Recently, van Linden et al. have
built up a database for kinase−ligand interaction (KLIFS) with
the published 3-D structures and have provided comprehensive
analysis of the binding modes.
5 Historically these binding modes
have been classiﬁed as type I, type II, type III, and type IV
depending on whether the compounds bind competitively with
ATP using the ‘DFG-in’ (type I) conformation or the ‘DFG-out’
(type II) conformation or noncompetitively by binding distal to
the ATP-binding pocket (type III and type IV). Although it
would be more appropriate to characterize inhibitors according
to how they impact the kinetic parameters of the kinase (kcat, KM
for ATP and substrate) and whether they display competitive,
noncompetitive, or mixed inhibition proﬁles, this approach
would have several practical limitations. First, this type of
enzymological analysis is almost never reported for new kinase
inhibitors, making it impossible to be used for classiﬁcation.
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tional and regulatory interactions in the cell that make it very
diﬃcult to determine a form of the enzyme that might serve as a
faithful representative of its intracellular state. In contrast, there
are a large and ever increasing number of inhibitor-kinase co-
crystal structures that have been determined using X-ray
crystallography that can be used to classify binding conforma-
tions. However, type I inhibitor-bound structures constitute the
majority of co-crystal structures, and structural data for type II
inhibitor complexes, especially for serine/threonine kinases, are
largely lacking. Crystallographically determined structures
provide an invaluable guide to medicinal chemists who seek to
understandhowchangestheymaketothesmallmoleculeimpact
its molecular recognition across the kinase family. Key to
successful implementation of this approach is the careful
correlation of changes in biochemical and cellular function
with observed structural changes.
■ REVIEW OF BINDING MODES
The most commonly observed binding mode, called ‘type I’,
involves the inhibitor binding to the ATP-site with the activation
loop assuming a conformation conducive to phosphate transfer.
Typically the inhibitor will possess some heterocyclic structure,
exploit the hydrophobic adenine binding pocket, and form zero
to three hydrogen bonds to the kinase ‘hinge segment’, which
serves to connect the N- and C-terminal kinase lobes. A classic
example is the EGFR inhibitor Geﬁtinib, where the quinazoline
core occupies the adenine binding area and makes one hydrogen
bond with Met793 in the hinge and two water-mediated
hydrogen bonds with Thr790 and Thr854, respectively (Figure
1A, B).
6,7
The type II binding mode was serendipitously discovered
when Imatinib was co-crystallized with Abl.
8 In contrast to the
presumedU-shapedbindingmodethatwouldberequiredforthe
compound to be accommodated in the DFG-in conformation,
the crystal structure demonstrated that the inhibitor bound in an
elongated conformation with the benzamide moiety of the
inhibitor displacing the phenylalanine of the DFG-motif. A
subsequently determined structure of Sorafenib with c-Raf
revealed an overall similar binding mode, which was termed a
‘type II’ binding mode.
9 Imatinib forms four critical hydrogen
bondswithAbl,whichincludeMet318tothepyridineN,Thr315
to aniline NH, Glu286 from the C-Helix to the amide oxygen,
and Asp381 from the ‘DFG-motif’ to the amide NH (Figure
1C).
10 Hydrogen bonds to Glu286 located in the C-Helix and
Asp381 from the ‘DFG-motif’ are formed by most type II
Figure 1. Representative X-ray structures and demonstration of binding modes. (A) ATP complexes with IRK (PDB ID: 1IR3) in type I binding. (B)
Geﬁtinib complexes with EGFR (PDB ID: 2ITY) in type I binding. (C) Imatinib complexes with Abl (PDB ID: 1IEP) in type II binding. (D) GNF-2
complexes with Abl (PDB ID: 3K5V) type IV binding. (E) Akt allosteric inhibitor complexes with Akt (PDB: 3O96); (F) PD318088 complexes with
MEK1(PDB:1S9J)intypeIIIbinding.(G)DasatinibcomplexeswithBTK(PDBID:3OCT).(H)PF-00215955complexeswithp38(PDBID:3K3I).
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a pharmacophore model that allows for the rational design of
compounds that have the potential to act as type II inhibitors.
11
A third category of kinase inhibitors is allosteric, sometimes
called ‘type IV’. To date, there are only a few well-characterized
allosteric inhibitors, most of which bind remotely from the ATP-
site such as the rapalogs,
12 GNF-2 and GNF-5,
13 as well as AKT
inhibitors such as MK2206.
14−16 GNF-2 and GNF-5 are
inhibitors of ABL that bind to the myristoyl-binding pocket
and facilitate an inhibitory latching of the SH3 and SH2 domains
onto the kinase domain
13 (Figure 1D). The non-ATP
competitive AKT inhibitor exerts its inhibitory function via
disrupting the interaction between the PH domain and kinase
domain
14 (Figure 1E) . Another well characterized class of
inhibitors called ‘type III’ are the MEK1 and 2 kinase inhibitors
such as PD318088,
17 CI-1040,
18 AZD6244,
19 TAK733,
20
GSK1120212,
21 and AS703026.
22 PD318088 binds to a
hydrophobic pocket directly adjacent to the ATP-binding site
and makes a hydrogen bond to the γ-phosphate of ATP (Figure
1F). PD318088 traps MEK1 kinase in a conformation where the
c-Helix and activation loop are in a noncatalytic conformation.
17
Other examples of allosteric binding have been observed for
JNKs, PAK1, CHK1, CK2, GSK3-β, PKC-δ, and p38, and a
discussion of their binding modes can be found in a recent
comprehensive review.
23
Some inhibitors have been observed to bind to conformations
that are intermediate between the fully DFG-in and DFG-out
conformations, For instance, dasatinib, typically classiﬁed as a
type I inhibitor, binds to BTK (PDB ID: 3OCT) with both
Asp539andPhe540ofthe‘DFGmotif’assumingaconformation
that is intermediate between the fully active and inactive states
24
(Figure 1G). In addition, some of the inhibitors such as p38
kinase inhibitor PF-00215955 stabilize the inactive (DFG-out)
conformation without occupying the adenine binding pocket
nearthehingearea stabilizingthebindingthrough twohydrogen
bonds with residues in the c-Helix and DFG motif and the
binding pocket created by DFG-out conformation
25 (Figure
1H).
Among the approved 23 kinase inhibitors that directly bind to
the kinase catalytic domain, 16 of them adopt a type I binding
modetotheirprimarytargets,6ofthemadoptthetypeIIbinding
mode, and 1 utilizes a type III binding mode (Figure 2). In
addition, there are over two dozen well-characterized type II
kinase inhibitors and among them at least 16 are under clinical
development for diﬀerent tumor indications (Figure 3 andTable
1).
■ CORRELATION OF SELECTIVITY AND KINASE
CONFORMATION
Achievinghighselectivityforkinaseinhibitorsisverychallenging
given the fact that the ATP-binding pocket’s spatial structure is
Figure 2. FDA-approved kinase inhibitors with binding modes.
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catalytically active conformation. However, despite this
similarity, highly selective inhibitors have been developed that
exploit subtle diﬀerences in sequence and 3-dimensional
structure of the ATP-binding cleft. Type I inhibitors typically
have a heterocyclic motif that makes 1−3 hydrogen bonds to the
hinge segment and that possess side-chains that introduce
contacts with less conserved regions of the ATP-binding pocket.
Several excellent reviews have been written about type I
inhibitors and they will not be further discussed here.
26−29
Type III inhibitors are usually the most selective as they exploit
binding pockets and regulatory mechanisms that are unique to a
particular kinase. Unfortunately, discovery ofallosteric inhibitors
islargelyanempiricalexercise,andrelativelyfewallosterickinase
inhibitors have been discovered to date.
A prevailing view was that type II inhibitors are intrinsically
more selective than type I inhibitors, which has served to spur
many type II medicinal chemistry campaigns. One rationale for
this commonly held belief is based on the observation that
inactive conformations of kinase are more dynamic than the
Figure 3. Examples of known type II kinase inhibitors.
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ized by Nobel et al. who state, “All active kinases are alike but an
inactive kinase is inactive after its own fashion.”
30 For example,
residues that surround the hydrophobic pocket created by the
DFG-out ﬂip are not as highly conserved as those in the ATP-
binding pocket, leading to the suggestion that type II inhibitors
might have a greater propensity for kinase selectivity relative to
type I inhibitors.
11 In addition, whether the DFG-out inactive
conformation can be generally accessed for all kinases is an
outstanding question. On the basis of the enumeration of the
currently solved kinase co-structures one might assume that type
II inhibition might be a relative rare phenomena.
31 It has been
postulated that type II binding modes might be most accessible
for kinases possessing a small ‘gatekeeper’ residue such as a
threonine.
32 Recently, however it has become clear that kinases
bearing medium-sized gatekeeper residues could also adopt a
type II binding mode.
33−35 Furthermore, why some kinases are
morepronetotypeIIinhibitorsisnotwellunderstoodassomeof
the crystalized apo inactive conformations have not been
targeted by type II inhibitors yet such as CDK6. Molecular
dynamics simulation studies with Abl suggest that binding mode
selection is dependent upon pH. However, whether this is
generally the case is not known.
36 Sequence and mutagenesis
studies of MAPK kinases have suggested that the gatekeeper
residue and the identity of the amino acid proceeding the DFG
motif are critical factors controlling the active and inactive
conformations.
37 It is therefore important to experimentally
determine the chemical features of the inhibitors and their target
kinases that make them susceptible to type II inhibition.
Table 1. Example of Type II Kinase Inhibitors under Clinical
Evaluation
drug name drug targets
clinical
development company
Nilotinib
(AMN-107)
BCR-Abl, c-Kit,
LCK,EphA3, EphA8
approved Novartis
Sorafenib
(Nexavar)
VEGFR, GFR, Raf approved Bayer/Onyx
Imatinib
(Gleevec)
BCR-Abl, c-Kit approved Novartis
Ponatinib BCR-Abl approved Ariad
Regorafenib c-Kit, VEGFR-2 approved Bayer
XL-184 MET, VEGFR-2, RET approved Exelixis
OSI-930 c-kit, VEGFR-2 phase I Astellas Pharma
Inc.
AMG-900 Aurora phase I Amgen
KX2-391 Src phase II Kinex Pharma Inc.
AC-220 Flt-3 phase II Ambit Biosciences
BMS777607 MET phase II Bristol-Myers
Squibb
GSK-1363089 MET, VEGFR-2, KDR phase II GlaxoSmithKline
AB1010 c-Kit, PDGFRs,
FGFR3
phase III AB Science
Apatinib
(YN968D)
VEGFR-2 phase III FhengRui
Medicine Co.
Figure 4. Analysis of X-ray crystal structure conﬁrmed type II conformation (DFG-out) kinases. (A) Treespot demonstration of type II conformation
(DFG-out)kinasedistribution.(B)Analysisofgatekeeperresidues.(C)DemonstrationofDFG-outA-loop-R(directtoC-Helix)conformation(PDB
ID: 1M52). (D) Demonstration of DFG-out A-loop-L (direct to Hinge) conformation (PDB ID: 1IEP).
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BINDING AS VERIFIED BY X-RAY
CRYSTALLOGRAPHY
In order to obtain an overview of which kinases can adopt the
type II binding, we analyzed the available X-ray kinase structures
(updated until June, 2013) in the protein data bank (PDB) and
studied their binding modes. This analysis revealed 48 kinases
adopted a type II (DFG-out) binding mode (Supplemental
Table 1). All groups of the kinome are represented in this set
including 27 of 90 kinases (30%) in the TK kinase group, 7 of 63
kinases (11%) in the CMGC group, 2 (4%) in the TKL group, 2
(2%) in the ‘other’ group, 3 (6%) in the STE group, 2 of 43
kinases (3%) in the AGC group, 4 of 74 kinases (5%) in the
CAMK groups, and 1 of 12 kinases (8%) in the casein kinase
(CK1) group (Figure 4A). Analysis of the gatekeeper residues
among these 48 kinases demonstrated that 15 kinases (31.3%)
possess methionine, 14 kinases (29.2%) possess threonine, 11
kinases (22.9%) possess phenylalanine, 3 kinases (6.3%) possess
leucine,3kinases(6.3%)possessisoleucine,and2kinases(4.2%)
possess valine (Figure 4B). In addition, we found that the
activation loop can either direct toward the hinge (L, 37/48) or
toward the αC-Helix (R, 11/48) (Figure 4C,D).
Figure 5. Schematic representation of type II kinase inhibitors constitution.
Figure 6. Chemical structures and S(1) score of 12 in-house generated/published inhibitors.
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inhibitors revealed that many of them share common structural
featuresthat ﬁtwellwithapreviously articulated pharmacophore
modelfortypeIIinhibitors
11(Supplemental Figure1andFigure
5). Similar to type I inhibitors, there usually is a ‘head’ hinge-
binding moiety, typically a heterocycle that occupies the region
normally occupied by the adenine of ATP. These head groups
can be decorated with various substitutions that can take
advantage of unique topological features of the kinase hinge, for
example the presence of a proline. Next to the ‘hinge-binding
moiety’ there is usually a ‘linker’ part segment that traverses the
region adjacent to the kinase gatekeeper residue. This linker
segmentisusually3−5chemicalbondlengthsandcanbeeithera
highly ﬂexible aliphatic chain or rigid aromatic ring systems. The
linkers need to carefully accommodate the identity of the
gatekeeper residue by either providing hydrogen bonding
functionality for the gatekeeper threonine or by leaving enough
space for kinases with large gatekeeper residues. Following the
linker segment is a hydrogen-bonding moiety that is required for
making conserved hydrogen bonds with the C-Helix and DFG
motif. Typically this hydrogen-bonding moiety is an amide or
urea. Kinase selectivity can be modulated by adjusting the ideal
location of this moiety. In some rare cases there is only one
hydrogen bond, and then this can be either an ether or an amine
linkage. The ﬁnal ‘tail’ segment typically consists of a
hydrophobic moiety that occupies the pocket created by the
DFG-out ﬂip. This ‘tail’sometimes contains a basic nitrogen that
improves water solubility and sometimes engages in additional
H-bondinginteractionswiththekinase.Despitetheusefulnessof
this model in constructing new potential type II inhibitors, it is
important to recognize a given inhibitor can adopt diﬀerent
binding modes to diﬀerent kinases. For example imatinib binds
to kinases such as Abl, c-Kit, and DDR1 in the classical extended
conformation but assumes a U-shape conformation when bound
toSyk(PDBID:1XBB).
38Indeed,acovalentversionofimatinib,
JNK-IN-8, co-crystallizes with JNK3 (PDB ID: 3V6S) as a type I
inhibitor using a U-shaped conformation.
39
■ ANALYSIS OF KINASES THAT ARE PREDICTED TO
ASSUME A TYPE II BINDING MODE BASED UPON
PHARMACOLOGICAL PROFILING
To complement the enumeration of kinases based on
experimentally conﬁrmed type II binding, we also evaluated
how many kinases could be potently targeted with a diverse
assortment of 36 type II kinase inhibitors that were subject to
proﬁling against panels of at least 400 kinases using DiscoveRx’s
KinomeScan technology, which can detect most type I, type II,
and other allosteric inhibitors.
40 This includes 12 inhibitors
(Figure 6, Supplemental Table 2) synthesized in our laboratory
aswellas24previouslypublishedtypeIIinhibitors(Figure3and
Supplemental Table 3).
41 Analysis of the selectivity S(1) scores
(the S score provides a measure of kinase selectivity with more
selective inhibitors exhibiting smaller S scores) of 12 inhibitors
reveals that the selectivity can range from highly selective (0.02)
to poor selectivity (0.30) (Figure 6 and Supplemental Figure 2).
We enumerated kinases that bound to inhibitors with an
apparent Kd (or IC50 <1μM, or KinomeScan Score <1) of at
least 1 μM based upon the KinomeScan technology. While we
expectthatthelargemajorityofthesekinaseswillbeboundinthe
type II conformation (DFG-out) (indeed of the 9 available
crystal structures with inhibitors in this set all bound as type II),
there may be some that bind as type I or using other
unanticipated binding modes. This analysis suggests that there
maybeupto220kinasesthatcanbetargetedevenbythislimited
compoundset,whichisaconsiderablylargernumberthanthe48
that have been crystallographically demonstrated to bind type II
inhibitors to date (Table 2). Among these 220 kinases predicted
to be sensitive to type II inhibitors, only 40 have been
crystallographically validated to bind in the type II conformation
(DFG-out) (Table 2, greenhighlight). Those 8 kinases that have
Table 2. Kinases That Bind Type II Kinase Inhibitors of the
Tested Set
a
aGreen color indicates the targets revealed both by X-ray and inhibitor
proﬁling analysis. Red color indicates those targets revealed only by X-
ray.
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were not revealed by this analysis is a consequence of these
kinases not being targeted by the chemical diversity represented
in this 36-member type-II kinase inhibitor set (Table 2, red
highlight). The distribution of the 220 kinases spanned all the
groups of the kinome including 80 of 90 TK family kinases
(89%), 22 of 43 TKL family kinases (51%), 17 of 74 CAMK
family kinases (23%), 39 of 63 CMGC family kinases (62%), 13
of 63 AGC family kinases (20%), 25 of 47 STE family kinases
(53%), 4 of 12 CK1 family kinases (33%), and 20 of 81 other
family kinases (25%) (Figure 7A). Sequence alignment revealed
that there was broad tolerance for diverse gatekeeper residues
with methionine accounting for 33%, threonine for 26%,
phenylalanine for 17.7%, leucine for 12.7%, and valine for
5.5%. It is worth noting that kinases possessing very large
gatekeeper residues such as isoleucine (2.3%), glutamic acid
(1%), as well as tyrosine (1%) can also be targeted by type II
inhibitors (Figure 7B). This follows almost the same trendas the
gatekeeper residues distribution among the full kinome,
suggesting that type II inhibitors do not display a strong bias
for the identity of the gatekeeper residue (Figure 7C). In this
inhibitor collection at least 10 type II inhibitors were capable of
inhibiting: BLK, CSF1R, DDR1/2, EPHA8, FLT3, JNK2, KIT,
LCK,LYN,LOKandMUSK,p38,PDGFRα/β,RET,SLK,SRC,
TAK1, TIE2, TRKC, VEGFR2, and ZAK (Figure 7D,E and
Supplemental Table 4). These kinases maybe be enriched in the
set simply because several of them, including FLT3, KIT, p38,
PDGFRα/β, RET, SRC, and VEGFR2, have been the subject of
extensive drug discovery eﬀorts that would result in an
enrichment in chemotypes with activity on these and related
kinases (Figure 7F). Further bioinformatical and structural
analysis will be required to elucidate whether there are currently
cryptic factors that predispose kinases to be prone to type II
inhibition.
Figure 7. Analysis of selectivity proﬁling revealed type II binding kinases. (A) Treespot demonstration of kinase distribution among kinome. (B)
Analysis of gatekeeper residues among the type II inhibitor targeted kinases. (C) Analysis of gatekeeper residues among the kinome. (D) Statistics of
mosttargetedkinases bytype II inhibitors. (E)Treespot demonstration of mosttargetedkinase distribution among kinome. (F) Analysisofgatekeeper
residues of most targeted kinases by type II inhibitors.
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INHIBITORS
Several diﬀerent strategies have been implemented to develop
type II kinase inhibitors. The most common approach is rational
designbaseduponthepharmacophoremodeldescribedabovein
conjunction with molecular modeling.
11,42−45 Frequently the
starting chemical scaﬀold was serendipitously found to be cross-
reactive with a new kinase of interest following a kinase proﬁling
experiment.
46 Another common approach is the ‘hybridization’
or ‘mix-n-match’ approach where validated fragments from one
scaﬀold are grafted onto another.
47,48 Several other interesting
approaches have been described that are yet not widely adopted.
For example, Erlanson et al. adopted the Well’s tethering
approach where a cysteine was used to screen a cysteine-reactive
thiol fragment library.
49 This approach resulted in the discovery
of a fragment that was subsequently elaborated to generate a
highly selective type II PDK1 kinase inhibitor.
50 Another
approach reported by Abagyan et al. has involved a computa-
tionalinvitroscreenagainstamodelofaDFG-outconformation
of the targeted kinase.
32 High-throughput biochemical assays
with highly activated recombinant enzymes is the typical
approach to discover type I kinase inhibitors and is sometimes
biased against type II compounds, which typically preferentially
bind to the dephosphorylated, inactive kinase. Rauh et al. have
developed an HTS compatible acrylodan-labeled kinase binding
assay that can distinguish between type I and type II binding and
demonstrated its utility to identify a highly selective p38α
inhibitor.
51,52Thesamegroupalsodevelopedaﬂuorescentbased
high-throughput assay format that utilized a hydrophobic
interaction between the P-loop and activation loop to identify
both the active and inactive conformation kinase inhibitors.
53
Laufer’sgrouphasdevelopedaconformation-speciﬁcﬂuorescent
polarization binding assay that was implemented to identify p38
inhibitorsthatpreferablybindtotheinactiveconformationofthe
kinase.
54 Vogel et al. developed a time-resolved ﬂuorescence
resonance energy transfer (TR-FRET) based binding assay that
allows the detection of both active or inactive conformation
kinase inhibitors and has been exploited in several studies.
55
■ PERSPECTIVES
Kinasesdisplayanimpressive degreeofconformational plasticity
that is undoubtedly one major contributor to the surprising
pharmacology that is frequently observed when kinase inhibitors
are used in vivo. Kinase structural biology has provided a wealth
of information as to diﬀerent kinase binding modes, but the
degree to which these snapshots are an accurate reﬂection of the
bonaﬁde intracellular inhibited kinase conformations remains an
open question. For example, imatinib has been observed to
crystallize with Abl and Src in virtually identical type II
conformations (DFG-out) yet displays 100- to 1000-fold more
potent biochemical and cellular inhibition of Abl versus Src.
Medicinal chemists have surmounted these challenges with the
empirical approach of correlating biochemical measurements
with structural biology and cellular measurements, which
frequently brings surprises. To date 6 of the 23 approved kinase
inhibitors would be classiﬁed as type II inhibitors. In addition,
theoretical analysis using entropy score as criteria revealed that
type II inhibitors might be generally more selective than type I
inhibitors.
56 These have motivated the development of better
methodologies that will improve our ability to rationally design
such inhibitors with a desired selectivity proﬁle. Our analysis of
existent crystal structures reveals 48 kinases that have been
observed in the DFG-out conformation. Using a collection of 36
type II inhibitors, we retrieved a set of 220 kinases that could be
targeted. However, while the majority of these are likely to be
targeted in the type II conformation (DFG-out), some may be
recognized in type I or currently unanticipated manners,
suggesting that more structural insight is needed into type II
inhibitor binding modes in particular for kinases families that are
poorly covered by the experimentally determined type II co-
crystal structures. In addition, we are clearly heavily biased based
upon the current selection of type II inhibitors, and the numbers
will change as diﬀerent chemotypes are added to the
pharmacopeia. Nonetheless our analysis helps shape some
general conclusions:
1. A signiﬁcant fraction of the kinome is likely targetable by
type II inhibitors, and there are a subset of kinases that seem to
have a predisposition for binding currently available type II
inhibitors.
2. The currently available type II inhibitors can range from
highly selective to highly nonselective. There does not appear to
be an inherent selectivity advantage to the type II binding mode.
3. There is a need to diversify the chemotypes being explored
as type II inhibitors, especially in the linker and tail region where
only a very limited number of pharmacophores have been
explored.
Another interesting area of active research is investigating the
diﬀerences in pharmacological eﬀects that can be attained with
type II versus type I inhibitors. For example, type I B-Raf kinase
inhibitors such as PLX4032 have been documented to have only
positive therapeutic eﬀects on tumors harboring the B-Raf
V600E mutation.
57,58 In contrast, type II B-Raf inhibitors have
been shown to block both the wild type and mutated B-Raf
kinases, which is believed to be a consequence of type II binding
preventing the transactivation that occurs as a result of B-Raf
hetero dimerization.
59 Type I and II inhibitors can also
complement each other in terms of the spectrum of mutations
that confer resistance to each. In addition, studies on c-Kit and
FMS kinase have revealed that they might naturally populate the
type II (DFG-out) conformation due to the JM domain
enforcing this conformation in a cellular context.
60 This raises
the question whether the type II conformation (DFG-out) is a
more native state for a particular subset of kinases. Therefore a
careful examination of the pharmacology generated by both type
I and type II inhibitors should be undertaken prior to deciding
whichmodeismostadvantageoustoagivendesiredendpoint.
61
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